These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 12866419)

  • 1. Clinical development of therapeutic recombinant proteins.
    Reichert JM; Paquette C
    Biotechniques; 2003 Jul; 35(1):176-8, 180, 182-5. PubMed ID: 12866419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant protein therapeutics--success rates, market trends and values to 2010.
    Pavlou AK; Reichert JM
    Nat Biotechnol; 2004 Dec; 22(12):1513-9. PubMed ID: 15583654
    [No Abstract]   [Full Text] [Related]  

  • 3. Therapeutic recombinant proteins: trends in US approvals 1982 to 2002.
    Reichert JM; Paquette C
    Curr Opin Mol Ther; 2003 Apr; 5(2):139-47. PubMed ID: 12772503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
    DiMasi JA
    Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trends in development and approval times for new therapeutics in the United States.
    Reichert JM
    Nat Rev Drug Discov; 2003 Sep; 2(9):695-702. PubMed ID: 12951576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development Times and Approval Success Rates for Drugs to Treat Infectious Diseases.
    DiMasi JA; Florez MI; Stergiopoulos S; Peña Y; Smith Z; Wilkinson M; Getz KA
    Clin Pharmacol Ther; 2020 Feb; 107(2):324-332. PubMed ID: 31502248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Under-representation of racial minorities in prostate cancer studies submitted to the US Food and Drug Administration to support potential marketing approval, 1993-2013.
    Wissing MD; Kluetz PG; Ning YM; Bull J; Merenda C; Murgo AJ; Pazdur R
    Cancer; 2014 Oct; 120(19):3025-32. PubMed ID: 24965506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulatory and scientific issues regarding use of foreign data in support of new drug applications in the United States: an FDA perspective.
    Khin NA; Yang P; Hung HM; Maung-U K; Chen YF; Meeker-O'Connell A; Okwesili P; Yasuda SU; Ball LK; Huang SM; O'Neill RT; Temple R
    Clin Pharmacol Ther; 2013 Aug; 94(2):230-42. PubMed ID: 23588316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic monoclonal antibodies: trends in development and approval in the US.
    Reichert JM
    Curr Opin Mol Ther; 2002 Apr; 4(2):110-8. PubMed ID: 12044031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Success rates for new drugs entering clinical testing in the United States.
    DiMasi JA
    Clin Pharmacol Ther; 1995 Jul; 58(1):1-14. PubMed ID: 7628176
    [No Abstract]   [Full Text] [Related]  

  • 11. Products approved in the United States for marketing during 2000.
    Pieniaszek HJ
    J Clin Pharmacol; 2001 May; 41(5):479-81. PubMed ID: 11361043
    [No Abstract]   [Full Text] [Related]  

  • 12. The role of the U.S. Food and Drug Administration review process: clinical trial endpoints in oncology.
    McKee AE; Farrell AT; Pazdur R; Woodcock J
    Oncologist; 2010; 15 Suppl 1():13-8. PubMed ID: 20237212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Indirect comparisons in the comparative efficacy and non-inferiority settings.
    Snapinn S; Jiang Q
    Pharm Stat; 2011; 10(5):420-6. PubMed ID: 21956948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends in risks associated with new drug development: success rates for investigational drugs.
    DiMasi JA; Feldman L; Seckler A; Wilson A
    Clin Pharmacol Ther; 2010 Mar; 87(3):272-7. PubMed ID: 20130567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2014 in review: FDA approval of new drugs.
    Kinch MS
    Drug Discov Today; 2017 Apr; 22(4):620-624. PubMed ID: 26100738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of multiple endpoints and approval paths depicts a decade of FDA oncology drug approvals.
    Shea MB; Roberts SA; Walrath JC; Allen JD; Sigal EV
    Clin Cancer Res; 2013 Jul; 19(14):3722-31. PubMed ID: 23665737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surviving sepsis--practice guidelines, marketing campaigns, and Eli Lilly.
    Eichacker PQ; Natanson C; Danner RL
    N Engl J Med; 2006 Oct; 355(16):1640-2. PubMed ID: 17050887
    [No Abstract]   [Full Text] [Related]  

  • 18. New biopharmaceuticals in the USA: trends in development and marketing approvals 1995-1999.
    Reichert JM
    Trends Biotechnol; 2000 Sep; 18(9):364-9. PubMed ID: 10942959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Approval success rates of drug candidates based on target, action, modality, application, and their combinations.
    Yamaguchi S; Kaneko M; Narukawa M
    Clin Transl Sci; 2021 May; 14(3):1113-1122. PubMed ID: 33831276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. US new drug applications increasingly rely on trials conducted abroad.
    Tanne JH
    BMJ; 2010 Jul; 341():c3616. PubMed ID: 20605887
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.